Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Completes First Royalty Payment to NanoLogix for Test Kit Technology
March 27, 2007

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that it has completed its first royalty payment to NanoLogix, Inc for the licensing rights to the technology used in the Designer Diagnostics test kits.

Designer Diagnostics is the wholly-owned medical device subsidiary of Nutra Pharma. The Company currently owns 11 patents and has licensed an additional 18 patents from NanoLogix that protect the technology surrounding the test kits.

“Not only does this royalty payment secure our licensing rights to the test kit technology, but it also confirms our commitment to building Designer Diagnostics and bringing the test kits to market,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We look forward to the future success of Designer Diagnostics and developing a closer relationship with NanoLogix over the next several years,” he added.

The Designer Diagnostics test kits are designed to provide rapid diagnosis and antibiotic-sensitivity testing of Tuberculosis (TB) and Nontuberculous Mycobacterium (NTM). The test kits are much less expensive and offer many benefits, including the ability to provide much earlier diagnosis and the ability to be easily integrated into any lab environment.

"Our licensing partnership with Nutra Pharma and the increasing demand for Designer Diagnostics test kits in Africa and Asia has enabled us to achieve a significant corporate goal of establishing a revenue stream from our patented intellectual property,” commented Bret T. Barnhizer, Chairman, CEO and President of NanoLogix. “We look forward to a long and rewarding partnership and association with Nutra Pharma and anticipate an ever-increasing revenue stream from that association,” he concluded.

Designer Diagnostics is currently in discussions with leading research institutions in the United States to complete human clinical trials for the test kits. Recently, the Company announced positive results of an in-vitro analysis. Normal culturing methods can take as long as 10 weeks to produce results, whereas Designer Diagnostics test kits showed similar results within 10 days.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The royalty payment to NanoLogix should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


May 31, 2017
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics